{"entity":{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","aka":[],"tldr":"Blue Earth Diagnostics makes Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.","summary":"Blue Earth Diagnostics, based in Oxford and a subsidiary of Bracco, makes the PET imaging agents Posluma, or flotufolastat F-18, also written 18F-rhPSMA-7.3, and Axumin, or fluciclovine F-18, for prostate cancer. Posluma was approved in 2023 on the LIGHTHOUSE and SPOTLIGHT trials, and a therapeutic rhPSMA analogue is in development, which would extend the radiohybrid platform from imaging into treatment. Nuclide links it to prostate cancer and to both tracer records. Whether a fluorine-18 PSMA agent with a matched therapeutic can win share from the gallium-68 tracers already established is the open question. Flotufolastat and fluciclovine have their own pages.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.blueearthdiagnostics.com"}],"tags":[],"related":["f-18","ga-68"],"indications":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["flotufolastat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07432633","nct07702292"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Oxford","country":"GB","companyType":"radiopharma","website":"https://www.blueearthdiagnostics.com","investors":[],"funding":[]},"route":"/companies/blue-earth-diagnostics/","neighbours":{"isotope":[{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"drug":[{"id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/"},{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/"}],"trial":[{"id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/"},{"id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/"},{"id":"falcon","kind":"trial","name":"FALCON","route":"/trials/falcon/"},{"id":"lighthouse","kind":"trial","name":"LIGHTHOUSE","route":"/trials/lighthouse/"},{"id":"spotlight","kind":"trial","name":"SPOTLIGHT","route":"/trials/spotlight/"}],"company":[{"id":"bracco","kind":"company","name":"Bracco Imaging","route":"/companies/bracco/"}],"section":[{"id":"f-molecular-imaging","kind":"section","name":"Molecular imaging","route":"/fronts/f-molecular-imaging/"}]}}